Kevin Kalinsky, MD

Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.

Panelists break down other key triple-negative breast cancer data presented at the 2025 ESMO Congress.

Panelists discuss findings from the TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan in immunotherapy-ineligible triple-negative breast cancer.

Panelists discuss sequencing considerations as more TROP-2–directed antibody-drug conjugates are evaluated in triple-negative breast cancer.

Panelists discuss safety considerations for sacituzumab govitecan–based therapy in frontline triple-negative breast cancer.

Panelists highlight findings from the ASCENT-03 trial evaluating sacituzumab govitecan in triple-negative breast cancer ineligible for immunotherapy.

Panelists break down data from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer.

Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer

Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.